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ABSTRACT 47 
 48 
Background: The development of CRISPR genome editing has transformed biomedical research. Most 49 
applications reported thus far rely upon the Cas9 protein from Streptococcus pyogenes SF370 (SpyCas9). With 50 
many RNA guides, wild-type SpyCas9 can induce significant levels of unintended mutations at near-51 
cognate sites, necessitating substantial efforts toward the development of strategies to minimize off-target 52 
activity. Although the genome-editing potential of thousands of other Cas9 orthologs remains largely 53 
untapped, it is not known how many will require similarly extensive engineering to achieve single-site 54 
accuracy within large (e.g. mammalian) genomes. In addition to its off-targeting propensity, SpyCas9 is 55 
encoded by a relatively large (~4.2 kb) open reading frame, limiting its utility in applications that require 56 
size-restricted delivery strategies such as adeno-associated virus vectors. In contrast, some genome-editing-57 
validated Cas9 orthologs (e.g. from Staphylococcus aureus, Campylobacter jejuni, Geobacillus stearothermophilus and 58 
Neisseria meningitidis) are considerably smaller and therefore better suited for viral delivery.  59 
Results: Here we show that wild-type NmeCas9, when programmed with guide sequences of natural 60 
length (24 nucleotides), exhibits a nearly complete absence of unintended editing in human cells, even 61 
when targeting sites that are prone to off-target activity with wildtype SpyCas9. We also validate at least 62 
six variant protospacer adjacent motifs (PAMs), in addition to the preferred consensus PAM (5’-N4GATT-63 
3’), for NmeCas9 genome editing in human cells.  64 
Conclusions: Our results show that NmeCas9 is a naturally high-fidelity genome editing enzyme and 65 
suggest that additional Cas9 orthologs may prove to exhibit similarly high accuracy, even without 66 
extensive engineering.  67 
 68 
Keywords: Cas9; CRISPR; sgRNA; Protospacer adjacent motif; off-target; Neisseria meningitidis  69 
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BACKGROUND 71 
 72 
Over the past decade, clustered, regularly interspaced, short palindromic repeats (CRISPRs) have 73 
been revealed as genomic sources of small RNAs (CRISPR RNAs, crRNAs) that specify genetic 74 
interference in many bacteria and most archaea [1-3]. CRISPR sequences include “spacers,” which often 75 
match sequences of previously encountered invasive nucleic acids such as phage genomes and plasmids. 76 
In conjunction with CRISPR-associated (Cas) proteins, crRNAs recognize target nucleic acids (DNA, 77 
RNA, or both, depending on the system) by base pairing, leading to their destruction. The primary 78 
natural function of CRISPR-Cas systems is to provide adaptive immunity against phages [4, 5] and other 79 
mobile genetic elements [6]. CRISPR-Cas systems are divided into two main classes: Class 1, with large, 80 
multi-subunit effector complexes, and Class 2, with single-protein-subunit effectors [7]. Both CRISPR-81 
Cas classes include multiple types based primarily on the identity of a signature effector protein. Within 82 
Class 2, the Type II systems are the most abundant and the best characterized. The interference function 83 
of Type II CRISPR-Cas systems requires the Cas9 protein, the crRNA, and a separate non-coding RNA 84 
known as the trans-activating crRNA (tracrRNA) [8-10]. Successful interference also requires that the 85 
DNA target (the “protospacer”) be highly complementary to the spacer portion of the crRNA, and that 86 
the PAM consensus be present at neighboring base pairs [11, 12]. 87 
Following the discovery that Type II interference occurs via double-strand breaks (DSBs) in the 88 
DNA target [9], the Cas9 protein was shown to be the only Cas protein required for Type II interference, 89 
to be manually reprogrammable via engineered CRISPR spacers, and to be functionally portable between 90 
species that diverged billions of years ago [10]. Biochemical analyses with purified Cas9 confirmed its role 91 
as a crRNA-guided, programmable nuclease that induces R-loop formation between the crRNA and one 92 
dsDNA strand, and that cleaves the crRNA-complementary and noncomplementary strands with its 93 
HNH and RuvC domains, respectively [13, 14]. In vitro cleavage reactions also showed that the tracrRNA 94 
is essential for DNA cleavage activity, and that the naturally separate crRNA and tracrRNA could retain 95 
function when fused into a single-guide RNA (sgRNA) [14]. Several independent reports then showed 96 
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that the established DSB-inducing activity of Cas9 could be elicited not only in vitro but also in living cells, 97 
both bacterial [15] and eukaryotic [16-20]. As with earlier DSB-inducing systems [21], cellular repair of 98 
Cas9-generated DSBs by either non-homologous end joining (NHEJ) or homology-directed repair (HDR) 99 
enabled live-cell targeted mutagenesis, and the CRISPR-Cas9 system has now been widely adopted as a 100 
facile genome-editing platform in a wide range of organisms [22-24]. In addition to genome editing, 101 
catalytically inactivated Cas9 (“dead” Cas9, dCas9) retains its sgRNA-guided DNA binding function, 102 
enabling fused or tethered functionalities to be delivered to precise genomic loci [25, 26]. Similar RNA-103 
guided tools for genome manipulations have since been developed from Type V CRISPR-Cas systems 104 
that use the Cas12a (formerly Cpf1) enzyme [27].   105 
Type II CRISPR-Cas systems are currently grouped into three subtypes (II-A, II-B and II-C) [7, 106 
28]. The vast majority of Cas9 characterization has been done on a single Type II-A ortholog, SpyCas9, 107 
in part due to its consistently high genome editing activity. SpyCas9’s sgRNAs typically contain a 20-nt 108 
guide sequence (the spacer-derived sequence that base pairs to the DNA target [8, 14]). The PAM 109 
requirement for SpyCas9 is 5’-NGG-3’ (or, less favorably, 5’-NAG-3’), after the 3’ end of the 110 
protospacer’s crRNA-noncomplementary strand [8, 14]. Based on these and other parameters, many 111 
sgRNAs directed against potentially targetable sites in a large eukaryotic genome also have near-cognate 112 
sites available to it that lead to unintended, “off-target” editing. Indeed, off-target activity by SpyCas9 has 113 
been well-documented with many sgRNA-target combinations [29, 30], prompting the development of 114 
numerous approaches to limit editing activity at unwanted sites [31-36]. Although these strategies have 115 
been shown to minimize off-targeting to various degrees, they do not always abolish it, and they can also 116 
reduce on-target activity, at least with some sgRNAs. Furthermore, each of these approaches has required 117 
extensive testing, validation, and optimization, and in some cases [33, 37, 38] depended heavily upon 118 
prior high-resolution structural characterization [39-42]. 119 
Thousands of other Cas9 orthologs have been documented [7, 28, 43, 44], providing tremendous 120 
untapped potential for additional genome editing capabilities beyond those offered by SpyCas9. Many 121 
Cas9 orthologs will provide distinct PAM specificities, increasing the number of targetable sites in any 122 
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given genome. Many pair-wise Cas9 combinations also have orthogonal guides that load into one 123 
ortholog but not the other, facilitating multiplexed applications [44-46]. Finally, some Cas9 orthologs 124 
(especially those from subtype II-C) are hundreds of amino acids smaller than the 1,368 amino acid 125 
SpyCas9 [7, 43, 44], and are therefore more amenable to combined Cas9/sgRNA delivery via a single 126 
size-restricted vector such as adeno-associated virus (AAV) [47, 48]. Finally, there may be Cas9 orthologs 127 
that exhibit additional advantages such as greater efficiency, natural hyper-accuracy, distinct activities, 128 
reduced immunogenicity, or novel means of control over editing. Deeper exploration of the Cas9 129 
population could therefore enable expanded or improved genome engineering capabilities. 130 
We have used N. meningitidis (strain 8013) as a model system for the interference functions and 131 
mechanisms of Type II-C CRISPR-Cas systems [49-52]. In addition, we and others previously reported 132 
that the Type II-C Cas9 ortholog from N. meningitidis (NmeCas9) can be applied as a genome engineering 133 
platform [46, 53, 54]. At 1,082 amino acids, NmeCas9 is 286 residues smaller than SpyCas9, making it 134 
nearly as compact as SauCas9 (1,053 amino acids) and well within range of all-in-one AAV delivery. Its 135 
spacer-derived guide sequences are longer (24 nts) than those of most other Cas9 orthologs [51], and like 136 
SpyCas9, it cleaves both DNA strands between the third and fourth nucleotides of the protospacer 137 
(counting from the PAM-proximal end). NmeCas9 also has a longer PAM consensus (5’-N4GATT-3’, 138 
after the 3’ end of the protospacer’s crRNA-noncomplementary strand) [44, 46, 51-54], leading to a lower 139 
density of targetable sites compared to SpyCas9. Considerable variation from this consensus is permitted 140 
during bacterial interference [46, 52], and a smaller number of variant PAMs can also support targeting 141 
in mammalian cells [53, 54]. Unlike SpyCas9, NmeCas9 has been found to cleave the DNA strand of 142 
RNA-DNA hybrid duplexes in a PAM-independent fashion [52, 55], and can also catalyze PAM-143 
independent, spacer-directed cleavage of RNA [56]. Recently, natural Cas9 inhibitors (encoded by 144 
bacterial mobile elements) have been identified and validated in N. meningitidis and other bacteria with 145 
type II-C systems, providing for genetically encodable off-switches for NmeCas9 genome editing [57, 58]. 146 
These “anti-CRISPR” (Acr) proteins [59] enable temporal, spatial, or conditional control over the 147 
NmeCas9 system. Natural inhibitors of Type II-A systems have also been discovered in Listeria 148 
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monocytogenes [60] and Streptococcus thermophilus [61], some of which are effective at inhibiting SpyCas9.  149 
The longer PAM consensus, longer guide sequence, or enzymological properties of NmeCas9 150 
could result in a reduced propensity for off-targeting, and targeted deep sequencing at bioinformatically 151 
predicted near-cognate sites is consistent with this possibility [54]. A high degree of genome-wide 152 
specificity has also been noted for the dNmeCas9 platform [62]. However, the true, unbiased accuracy of 153 
NmeCas9 is not known, since empirical assessments of genome-wide off-target editing activity 154 
(independent of bioinformatics prediction) have not been reported for this ortholog. Here we define and 155 
confirm many of the parameters of NmeCas9 editing activity in mammalian cells including PAM 156 
sequence preferences, guide length limitations, and off-target profiles. Most notably, we use two empirical 157 
approaches (GUIDE-seq [63] and SITE-Seq [64] to define NmeCas9 off-target profiles and find that 158 
wild-type NmeCas9 is a high-fidelity genome editing platform in mammalian cells, with far lower levels of 159 
off-targeting than wild-type SpyCas9. These results further validate NmeCas9 as a genome engineering 160 
platform, and suggest that continued exploration of Cas9 orthologs could identify additional RNA-guided 161 
nucleases that exhibit favorable properties, even without the extensive engineering efforts that have been 162 
applied to SpyCas9 [31, 34, 35].  163 
 164 
RESULTS 165 
 166 
Co-expressed sgRNA increases NmeCas9 accumulation in mammalian cells 167 
Previously we demonstrated that NmeCas9 (derived from N. meningitidis strain 8013 [51]) can 168 
efficiently edit chromosomal loci in human stem cells using either dual RNAs (crRNA + tracrRNA) or a 169 
sgRNA [53]. To further define the efficacy and requirements of NmeCas9 in mammalian cells, we first 170 
constructed an all-in-one plasmid (pEJS15) that delivers both NmeCas9 protein and a sgRNA in a single 171 
transfection vector, similar to our previous all-in-one dual-RNA plasmid (pSimple-Cas9-Tracr-crRNA; 172 
Addgene #47868) [53]. The pEJS15 plasmid expresses NmeCas9 fused to a C-terminal single-HA epitope 173 
tag and nuclear localization signal (NLS) sequences at both N- and C-termini under the control of the 174 
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elongation factor-1α (EF1α) promoter. The sgRNA cassette (driven by the U6 promoter) includes two 175 
BsmBI restriction sites that are used to clone a spacer of interest from short, synthetic oligonucleotide 176 
duplexes. First, we cloned three different bacterial spacers (spacers 9, 24 and 25) from the endogenous N. 177 
meningitidis CRISPR locus (strain 8013) [51, 52] to express sgRNAs that target protospacer (ps) 9, ps24 or 178 
ps25, respectively (Supplemental Fig. 1A). None of these protospacers have cognate targets in the human 179 
genome. We also cloned a spacer sequence to target an endogenous genomic NmeCas9 target site (NTS) 180 
from chromosome 10 that we called N-TS3 (Table 1). Two of the resulting all-in-one plasmids  181 
Table 1. NmeCas9 or SpyCas9 guide and target sequences used in this study. NTS, NmeCas9 target site; STS, 182 
SpyCas9 target site. The sgRNA spacer sequences (5’à3’) are shown with their canonical lengths, and with a 5’-183 
terminal G residue; non-canonical lengths are described in the text and figures. Target site sequences are also 5’à3’ 184 
and correspond to the DNA strand that is non-complementary to the sgRNA, with PAM sequences underlined.  185 
 186 
(spacer9/sgRNA and N-TS3/sgRNA), as well as a plasmid lacking the sgRNA cassette, were transiently 187 
transfected into HEK293T cells for 48 hours, and NmeCas9 expression was assessed by anti-HA western 188 
Site Gene or locus 
Spacer Sequence  
of sgRNA Target site, with PAM 
NTS1B SLC9A9 GGGCAUCAUGAUUUUGAACUCCCU CCTTGGCATCATGATTTTGAACTCCCTATGTGATTCTA 
NTS1C SLC9A9 GUGGUCUGGGGUACAGCCUUGGCA TACTUGGTCTGGGGTACAGCCTTGGCATCATGATTTTG 
NTS1C-OT1 PHKG2 GCGGUGUGAGGUACAGCCUUGGCA TAATCGGTGTGAGGTACAGCCTTGGCATCAGGATTTCT 
NTS3 AL158836 GAUGCUCAGAAAGAGGAAGCUGGU GGGGATGCTCAGAAAGAGGAAGCTGGTTTATGATTGGA 
NTS4B FLJ00328 GGACAGGAGUCGCCAGAGGCCGGU GCAGGACAGGAGTCGCCAGAGGCCGGTGGTGGATTTCC 
NTS4C FLJ00328 GGGGCUGGCUCCACGUCGCGCCGC TGCGGGGCTGGCTCCACGTCGCGCCGCGGCGGTTTGGG 
NTS5 AF064860 GAAACAGACUCGCAAGACUUCAGA GACAAAACAGACTCGCAAGACTTCAGATACAGATTCCA 
NTS7 LOC100505797 GAGGGAGAGAGGUGAGCGGAUGAA GCAAAGGGAGAGAGGTGAGCGGATGAAGGGAGATTGGT 
NTS8 ESPN GGACGCAAUUCCAGAGGUGAUGGG CGGCGACGCAATTCCAGAGGTGATGGGGAGTGATTGTC 
NTS9 ZNHIT2 GGCGCUGUGUUUUCGCAAAGCUUC CGGCGCGCTGTGTTTTCGCAAAGCTTCCGAGGATTCTC 
NTS10 HHLA1 GCAGCCAAGUUUGAGAACUGCUGU TGTGCAGCCAAGTTTGAGAACTGCTGTTACAGATTTCC 
NTS11 SMARCB1 GUUCCAGUUGGGAAGGGCCAGUGC TAGATTCCAGTTGGGAAGGGCCAGTGCCTCCGATTCCA 
NTS21 TNNC1 GCCAGAGCUGCCGCCAGACAGUGA CAGTCCAGAGCTGCCGCCAGACAGTGATGCTGTCTTGG 
NTS25 AC193513 GGUUUCUCAUCCUGUCUUCUGCCU CCGCGTTTCTCATCCTGTCTTCTGCCTAGTGGATATGT 
NTS26 LOC105378512 GUUCAAAAGUAGCGGGCGCUAGGC GTACTTCAAAAGTAGCGGGCGCTAGGCGGGTGTTTCTG 
NTS27 TIE1 GUUCUCCAAGCCCUCGGACCUCGU CGGCTTCTCCAAGCCCTCGGACCTCGTGGGCGTCTTCT 
NTS30 NEK8 GGGGCUCCGGAGCCCACCCCAGGA CGCGGGGCTCCGGAGCCCACCCCAGGACCAGGACTTAG 
NTS31 POC1A GUGGGAAGUGUAGCUCCACCUUCC ATGTTGGGAAGTGTAGCTCCACCTTCCTCCAGACATAG 
NTS32 VEGFA GCCCCGGCUCUGGCUAAAGAGGGA CACACCCCGGCTCTGGCTAAAGAGGGAATGGGCTTTGG 
NTS33 VEGFA GCGGGGAGAAGGCCAGGGGUCACU GGAGCGGGGAGAAGGCCAGGGGTCACTCCAGGATTCCA 
NTS55 CYBB GCUGGAUUACUGUGUGGUAGAGGG CTAGCTGGATTACTGTGTGGTAGAGGGAGGTGATTAGC 
NTS58 AAVS1 GUUUGCCUGGACACCCCGUUCUCC TTTCTTTGCCTGGACACCCCGTTCTCCTGTGGATTCGG 
NTS59 AAVS1 GACCCCACAGUGGGGCCACUAGGG CTCCACCCCACAGTGGGGCCACTAGGGACAGGATTGGT 
STS60 AAVS1 GUUAAUGUGGCUCUGGUUCU CCGGTTAATGTGGCTCTGGTTCTGGGTAC 
STS61 AAVS1 GUCCCCUCCACCCCACAGUG TCTGTCCCCTCCACCCCACAGTGGGGCCA 
STS62 AAVS1 GGGGCCACUAGGGACAGGAU AGTGGGGCCACTAGGGACAGGATTGGTGA 
NTS63 AAVS1 GAGUUAGAACUCAGGACCAACUUA CCAAAGTTAGAACTCAGGACCAACTTATTCTGATTTTG 
NTS64 Rosa26 GGCAGAUCACGAGGGAAGAGGGGG AGTTGCAGATCACGAGGGAAGAGGGGGAAGGGATTCTC 
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blot (Fig. 1A). As a positive control we also included a sample transfected with a SpyCas9-expressing 189 
plasmid (triple-HA epitope-tagged, and driven by the cytomegalovirus (CMV) promoter) [65] (Addgene 190 
#69220). Full-length NmeCas9 was efficiently expressed in the presence of both sgRNAs (lanes 3 and 4). 191 
However, the abundance of the protein was much lower in the absence of sgRNA (lane 2). A different 192 
Type II-C Cas9 (CdiCas9) was shown to be dramatically stabilized by its cognate sgRNA when subjected 193 
to proteolysis in vitro [55]; if similar resistance to proteolysis occurs with NmeCas9 upon sgRNA binding, it 194 
could explain some or all of the sgRNA-dependent increase in cellular accumulation. 195 
 196 
Efficient editing in mammalian cells by NmeCas9  197 
To establish an efficient test system for NmeCas9 activity in mammalian cells, we used a co-198 
transfected fluorescent reporter carrying two truncated, partially overlapping GFP fragments that are 199 
separated by a cloning site [66] into which we can insert target protospacers for NmeCas9. Cleavage 200 
promotes a single-strand-annealing-based repair pathway that generates an intact GFP open reading 201 
frame (ORF), leading to fluorescence [66] that can be scored after 48 hours by flow cytometry. We 202 
generated reporters carrying three validated bacterial protospacers (ps9, ps24 and ps25, as described 203 
above) [51, 52] for transient cotransfection into HEK293T cells along with the corresponding 204 
NmeCas9/sgRNA constructs. Figure 1B shows that all three natural protospacers of NmeCas9 can be 205 
edited in human cells and the efficiency of GFP induction was comparable to that observed with SpyCas9 206 
(Fig. 1B). 207 
Next, we reprogrammed NmeCas9 by replacing the bacterially-derived spacers with a series of 208 
spacers designed to target eleven human chromosomal sites with an N4GATT PAM (Table 1). These 209 
sgRNAs induced insertion/deletion (indel) mutations at all sites tested, except NTS10 (Fig. 1C, lanes 23-210 
25), as determined by T7 Endonuclease 1 (T7E1) digestion (Fig. 1C). The editing efficiencies ranged from 211 
5% for NTS1B site to 47% in the case of NTS33 (Fig. 1D), though T7E1 tends to underestimate the true 212 
frequencies of indel formation [67]. These data confirm that NmeCas9 can induce, with variable 213 
efficiency, edits at many genomic target sites in human cells. Furthermore, we demonstrated NmeCas9 214 
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genome editing in multiple cell lines and via distinct delivery modes. Nucleofection of NmeCas9 215 
ribonucleoprotein (RNP) (loaded with an in vitro-transcribed sgRNA) led to indel formation at three sites in 216 
K562 chronic myelogenous leukemia cells and in hTERT-immortalized human foreskin fibroblasts (gift 217 
from Dr. Job Dekker) (Fig. 1E). In addition, mouse embryonic stem cells (mESCs) and HEK293T cells 218 
were transduced with a lentivirus construct expressing NmeCas9. In these cells, transient transfection of 219 
plasmids expressing a sgRNA led to genome editing (Fig. 1E). Collectively, our results show that 220 
NmeCas9 can be used for genome editing in a range of human or mouse cell lines via plasmid 221 
transfection, RNP delivery, or lentiviral transduction. 222 
 223 
Functionality of truncated sgRNAs with NmeCas9  224 
SpyCas9 can accommodate limited variation in the length of the guide region (normally 20 225 
nucleotides) of its sgRNAs [68-71], and sgRNAs with modestly lengthened (22-nt) or shortened (17–18-nt) 226 
guide regions can even enhance editing specificity by reducing editing at off-target sites by a greater 227 
degree than they affect editing at the on-target site [68, 69]. To test the length dependence of the 228 
NmeCas9 guide sequence (normally 24 nucleotides; [51]) during mammalian editing, we constructed a 229 
series of sgRNAs containing 18, 19, 20, 21, 22, 23, and 24 nucleotides of complementarity to ps9 cloned 230 
into the split-GFP reporter plasmid (Supplemental Fig. 1B). All designed guides started with two guanine 231 
nucleotides (resulting in 1-2 positions of target non-complementarity at the very 5’ end of the guide) to 232 
facilitate transcription and to test the effects of extra 5’-terminal G residues, analogous to the SpyCas9 233 
“GGN20” sgRNAs [68]. We then measured the abilities of these sgRNAs to direct NmeCas9 cleavage of 234 
the reporter in human cells. sgRNAs that have 20–23 nucleotides of target complementarity showed 235 
activities comparable to the sgRNA with the natural 24 nucleotides of complementarity, whereas sgRNAs 236 
containing 18 or 19 nucleotides of complementarity show lower activity (Fig. 2A).  237 
We next used a native chromosomal target site (NTS33 in VEGFA, as in Figs. 1C and 1D) to test 238 
the editing efficiency of NmeCas9 spacers of varying lengths (Supplemental Fig. 1C). sgRNA constructs 239 
included one or two 5’-terminal guanine residues to enable transcription by the U6 promoter, sometimes 240 
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resulting in 1–2 nucleotides of target non-complementarity at the 5’ end of the guide sequence. sgRNAs 241 
with 20, 21, or 22 nucleotides of target complementarity (GGN18, GGN19, and GGN20, respectively) 242 
performed comparably to the natural guide length (24 nucleotides of complementarity, GN23) at this site 243 
(Fig. 2B-C), and within this range, the addition of 1–2 unpaired G residues at the 5’ end had no adverse 244 
effect. These results are consistent with the results obtained with the GFP reporter (Fig. 2A). sgRNAs with 245 
guide lengths of 19 nucleotides or shorter, along with a single mismatch in the first or second position 246 
(GGN17, GGN16, and GGN15), did not direct detectable editing, nor did a sgRNA with perfectly matched 247 
guide sequences of 17 or 14 nucleotides (GN16 and GN13, respectively) (Fig. 2B-C). However, a 19-nt 248 
guide with no mismatches (GN18) successfully directed editing, albeit with slightly reduced efficiency. 249 
These results indicate that 19–26-nt guides can be tolerated by NmeCas9, but that activity can be 250 
compromised by guide truncations from the natural length of 24 nucleotides down to 17–18 nucleotides 251 
and smaller, and that single mismatches (even at or near the 5’-terminus of the guide) can be 252 
discriminated against with a 19-nt guide.   253 
The target sites tested in Figs. 2A and 2B-C are both associated with a canonical N4GATT PAM,  254 
but efficient NmeCas9 editing at mammalian chromosomal sites associated with N4GCTT [53] and other 255 
variant PAMs [[54]; also see below] has also been reported. To examine length dependence at a site with 256 
a variant PAM, we varied guide sequence length at the N4GCTT-associated NTS32 site (also in VEGFA). 257 
In this experiment, each of the guides had two 5’-terminal G residues, accompanied by 1–2 terminal 258 
mismatches with the target sequence (Supplemental Fig. 1D). At the NTS32 site, sgRNAs with 21–24 259 
nucleotides of complementarity (GGN24, GGN23, GGN22, and GGN21) supported editing, but shorter 260 
guides (GGN20, GGN19, and GGN18) did not (Fig. 2D-E). We conclude that sgRNAs with 20 nucleotides 261 
of complementarity can direct editing at some sites (Fig. 2B-C) but not all (Fig. 2D-E). It is possible that 262 
this minor variation in length dependence can be affected by the presence of mismatched 5’-terminal G 263 
residues in the sgRNA, the adherence of the target to the canonical N4GATT PAM consensus, or both, 264 
but the consistency of any such relationship will require functional tests at much larger numbers of sites. 265 
Nonetheless, NmeCas9 guide truncations of 1–3 nucleotides appear to be functional in most cases, in 266 
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agreement with the results of others [54].   267 
 268 
PAM specificity of NmeCas9 in human cells  269 
During native CRISPR interference in bacterial cells, considerable variation in the N4GATT 270 
PAM consensus is tolerated: although the G1 residue (N4GATT) is strictly required, virtually all other 271 
single mutations at A2 (N4GATT), T3 (N4GATT), and T4 (N4GATT) retain at least partial function in 272 
licensing bacterial interference [46, 52]. In contrast, fewer NmeCas9 PAM variants have been validated 273 
during genome editing in mammalian cells [53, 54]. To gain more insight into NmeCas9 PAM flexibility 274 
and specificity in mammalian cells, and in the context of an otherwise identical target site and an invariant 275 
sgRNA, we employed the split-GFP readout of cleavage activity described above. We introduced single-276 
nucleotide mutations at every position of the PAM sequence of ps9, as well as all double mutant 277 
combinations of the four most permissive single mutants, and then measured the ability of NmeCas9 to 278 
induce GFP fluorescence in transfected HEK293T cells. The results are shown in Fig. 3A. As expected, 279 
mutation of the G1 residue to any other base reduced editing to background levels, as defined by the 280 
control reporter that lacks a protospacer [(no ps), see Fig. 3A]. As for mutations at the A2, T3 and T4 281 
positions, four single mutants (N4GCTT, N4GTTT, N4GACT, and N4GATA) and two double mutants 282 
(N4GTCT and N4GACA) were edited with efficiencies approaching that observed with the N4GATT 283 
PAM. Two other single mutants (N4GAGT and N4GATG), and three double mutants (N4GCCT, 284 
N4GCTA, and N4GTTA) gave intermediate or low efficiencies, and the remaining mutants tested were at 285 
or near background levels. We note that some of the minimally functional or non-functional PAMs (e.g. 286 
N4GAAT and N4GATC) in this mammalian assay fit the functional consensus sequences defined 287 
previously in E. coli [46]. 288 
We then used T7E1 analysis to validate genome editing at eight native chromosomal sites 289 
associated with the most active PAM variants (N4GCTT, N4GTTT, N4GACT, N4GATA, N4GTCT, and 290 
N4GACA). Our results with this set of targets indicate that all of these PAM variants tested except 291 
N4GACA support chromosomal editing (Fig. 3B and C). 292 
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 293 
Apo NmeCas9 is not genotoxic to mammalian cells 294 
NmeCas9 and several other type II-C Cas9 orthologs have been shown to possess an RNA-295 
dependent ssDNA cleavage (DNase H) activity in vitro [52, 55]. R-loops (regions where an RNA strand 296 
invades a DNA duplex to form a DNA:RNA hybrid, with the other DNA strand displaced) occur 297 
naturally during transcription and other cellular processes [72]. Since DNase H activity is independent of 298 
the tracrRNA or the PAM sequence, it is theoretically possible that it could degrade naturally-occurring 299 
R-loops in living cells. Global degradation of R-loops in cells could result in an increase in DNA damage 300 
detectable by increased γH2AX staining [73]. To test whether the DNase H activity of NmeCas9 could 301 
lead to an increase in γH2AX, we transduced mouse embryonic stem cells E14 (mESCs) with lentiviral 302 
plasmids expressing NmeCas9 and dNmeCas9 (which lacks DNase H activity; [52]). mESCs are ideal for 303 
this purpose as R-loops have been extensively studied in these cells and have been shown to be important 304 
for differentiation [74]. We performed γH2AX staining of these two cell lines and compared them to 305 
wildtype E14 cells. As a positive control for γH2AX induction, we exposed wildtype E14 cells to UV, a 306 
known stimulator of the global DNA damage response. Immunofluorescence microscopy of cells 307 
expressing NmeCas9 or dNmeCas9 exhibited no increase in γH2AX foci compared to wildtype E14, 308 
suggesting that sustained NmeCas9 expression is not genotoxic (Supplemental Fig. 2A). In contrast, cells 309 
exposed to UV light showed a significant increase in γH2AX levels. Flow cytometric measurements of 310 
γH2AX immunostaining confirmed these results (Supplemental Fig. 2B). These data suggest that 311 
NmeCas9 expression does not lead to a global DNA damage response in mESCs. 312 
 313 
Comparative analysis of NmeCas9 and SpyCas9 314 
SpyCas9 is by far the best-characterized Cas9 orthologue, and is therefore the most informative 315 
benchmark when defining the efficiency and accuracy of other Cas9s. To facilitate comparative 316 
experiments between NmeCas9 and SpyCas9, we developed a matched Cas9 + sgRNA expression system 317 
for the two orthologs. This serves to minimize the expression differences between the two Cas9s in our 318 
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comparative experiments, beyond those differences dictated by the sequence variations between the 319 
orthologues themselves. To this end, we employed the separate pCSDest2-SpyCas9-NLS-3XHA-NLS 320 
(Addgene #69220) and pLKO.1-puro-U6sgRNA-BfuA1 (Addgene #52628) plasmids reported previously 321 
for the expression of SpyCas9 (driven by the CMV promoter) and its sgRNA (driven by the U6 promoter), 322 
respectively [58, 65]. We then replaced the bacterially-derived SpyCas9 sequence (i.e., not including the 323 
terminal fusions) with that of NmeCas9 in the CMV-driven expression plasmid.  This yielded an 324 
NmeCas9 expression vector (pEJS424) that is identical to that of the SpyCas9 expression vector in every 325 
way (backbone, promoters, UTRs, poly(A) signals, terminal fusions, etc.) except for the Cas9 sequence 326 
itself. Similarly, we replaced the SpyCas9 sgRNA cassette in pLKO.1-puro-U6sgRNA-BfuA1 with that of 327 
the NmeCas9 sgRNA [46, 53], yielding the NmeCas9 sgRNA expression plasmid pEJS333. This matched 328 
system facilitates direct comparisons of the two enzymes’ accumulation and activity during editing 329 
experiments. To assess relative expression levels of the identically-tagged Cas9 orthologs, the two plasmids 330 
were transiently transfected into HEK293T cells for 48 hours, and the expression of the two proteins was 331 
monitored by anti-HA western blot (Fig. 4A). Consistent with our previous data (Fig. 1A), analyses of 332 
samples from identically transfected cells show that NmeCas9 accumulation is stronger when co-expressed 333 
with its cognate sgRNA (Fig. 4A, compare lane 6 to 4 and 5), whereas SpyCas9 is not affected by the 334 
presence of its sgRNA (lanes 1-3).  335 
For an initial comparison of the cleavage efficiencies of the two Cas9s, we chose three previously 336 
validated SpyCas9 guides targeting the AAVS1 “safe harbor” locus [20, 75] and used the CRISPRseek 337 
package [76] to design three NmeCas9 guides targeting the same locus within a region of ~700 base pairs 338 
(Supplemental Fig. 3A). The matched Cas9/sgRNA expression systems described above were used for 339 
transient transfection of HEK293T cells. T7E1 analysis showed that the editing efficiencies were 340 
comparable, with the highest efficiency being observed when targeting the NTS59 site with NmeCas9 341 
(Fig. 4B and Supplemental Fig. 3B).  342 
To provide a direct comparison of editing efficiency between the SpyCas9 and NmeCas9 systems, 343 
we took advantage of the non-overlapping PAMs of SpyCas9 and NmeCas9 (NGG and N4GATT, 344 
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respectively). Because the optimal SpyCas9 and NmeCas9 PAMs are non-overlapping, it is simple to 345 
identify chromosomal target sites that are compatible with both orthologues, i.e. that are dual target sites 346 
(DTSs) with a composite PAM sequence of NGGNGATT that is preferred by both nucleases. In this 347 
sequence context, both Cas9s will cleave the exact same internucleotide bond (NN/NNNNGGNGATT; 348 
cleaved junction in bold, and PAM region underlined), and both Cas9s will have to contend with the 349 
exact same sequence and chromatin structural context. Furthermore, if the target site contains a G residue  350 
at position -24 of the sgRNA-noncomplementary strand (relative to the PAM) and another at position -20, 351 
then the U6 promoter can be used to express perfectly-matched sgRNAs for both Cas9 orthologues. Four 352 
DTSs with these characteristics were used in this comparison (Supplemental Fig. 4A). We had previously 353 
used NmeCas9 to target a site (NTS7) that happened also to match the SpyCas9 PAM consensus, so we 354 
included it in our comparative analysis as a fifth site, even though it has a predicted rG-dT wobble pair at 355 
position -24 for the NmeCas9 sgRNA (Supplemental Fig. 4A). 356 
We set out next to compare the editing activities of both Cas9 orthologs programmed to target the 357 
five chromosomal sites depicted in Supplemental Fig. 4A, initially via T7E1 digestion. SpyCas9 was more 358 
efficient than NmeCas9 at generating lesions at the DTS1 and DTS8 sites (Fig. 4C, lanes 1-2 and 13-14). 359 
In contrast, NmeCas9 was more efficient than SpyCas9 at the DTS3 and NTS7 sites (Fig. 4C, lanes 5-6 360 
and 17-18). Editing at DTS7 was approximately equal with both orthologs (Fig. 4C, lanes 9-10). Data 361 
from three biological replicates of all five target sites are plotted in Fig. 4D. The remainder of our 362 
comparative studies focused on DTS3, DTS7, and DTS8, as they provided examples of target sites with 363 
NmeCas9 editing efficiencies that are greater than, equal to, or lower than those of SpyCas9, respectively. 364 
At all three of these sites, the addition of an extra 5’-terminal G residue had little to no effect on editing by 365 
either SpyCas9 or NmeCas9 (Supplemental Fig. 4B). Truncation of the three NmeCas9 guides down to 366 
20 nucleotides (all perfectly matched) again had differential effects on editing efficiency from one site to 367 
the next, with no reduction in DTS7 editing, partial reduction in DTS3 editing, and complete loss of 368 
DTS8 editing (Supplemental Fig. 4B).  369 
 370 
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Assessing the genome-wide precision of NmeCas9 editing 371 
All Cas9 orthologs described to date have some propensity to edit off-target sites lacking perfect 372 
complementarity to the programmed guide RNA, and considerable effort has been devoted to developing 373 
strategies (mostly with SpyCas9) to increase editing specificity (reviewed in [31, 34, 35]). In comparison 374 
with SpyCas9, orthologs such as NmeCas9 that employ longer guide sequences and that require longer 375 
PAMs have the potential for greater on-target specificity, possibly due in part to the lower density of near-376 
cognate sequences. As an initial step in exploring this possibility, we used CRISPRseek [76] to perform a 377 
global analysis of potential NmeCas9 and SpyCas9 off-target sites with six or fewer mismatches in the 378 
human genome, using sgRNAs specific for DTS3, DTS7 and DTS8 (Fig. 5A) as representative queries. 379 
When allowing for permissive and semi-permissive PAMs (NGG, NGA, and NAG for SpyCas9; 380 
N4GHTT, N4GACT, N4GAYA, and N4GTCT for NmeCas9), potential off-target sites for NmeCas9 381 
were predicted with two to three orders of magnitude lower frequency than for SpyCas9 (Table 2). 382 
Furthermore, NmeCas9 off-target sites with fewer than five mismatches were rare (two sites with four 383 
Number of 
mismatches 
SpyCas9 sites  
(NGG, NGA, NAG PAMs) 
NmeCas9 sites (N4GATT, N4GCTT, 
N4GTTT, N4GACT, N4GATA, 
N4GTCT, N4GACA PAMs) 
DTS3 DTS7 DTS8 DTS3 DTS7 DTS8 
1 0 0 0 0 0 0 
2 4 2 2 0 0 0 
3 45 52 60 0 0 0 
4 680 500 772 0 2 0 
5 6,691 4,116 7,325 4 5 25 
6 45,897 26,474 52,547 17 61 129 
Total 53,317 31,144 60,706 21 68 154 
Table 2. Number of predicted near-cognate sites in the human genome for the three dual target sites (DTS3, DTS7 384 
and DTS8) analyzed in this study. These potential off-target sites differ from the on-target site by six or fewer 385 
mismatches, as listed on the left, and include the functional or semi-functional PAMs shown at the top.   386 
mismatches) for DTS7, and non-existent for DTS3 and DTS8 (Table 2). Even when we relaxed the 387 
NmeCas9 PAM requirement to N4GN3, which includes some PAMs that enable only background levels of 388 
targeting (e.g. N4GATC (Fig. 3A)), the vast majority of predicted off-target sites (>96%) for these three 389 
guides had five or more mismatches, and none had fewer than four mismatches (Fig. 5A). In contrast, the 390 
SpyCas9 guides targeting DTS3, DTS7, and DTS8 had 49, 54, and 62 predicted off-target sites with 391 
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three or fewer mismatches, respectively (Table 2). As speculated previously [53, 54], these bioinformatic 392 
predictions suggest the intriguing possibility that the NmeCas9 genome editing system may induce very 393 
few undesired mutations, or perhaps none, even when targeting sites that induce substantial off-targeting 394 
with SpyCas9.  395 
Although bioinformatic predictions of off-targeting can be useful, it is well established that off- 396 
target profiles must be defined experimentally in a prediction-independent fashion due to our limited 397 
understanding of target specificity determinants, and the corresponding inability of algorithms to predict 398 
all possible sites successfully [31, 34, 35]. The need for empirical off-target profiling is especially acute 399 
with Cas9 orthologs that are far less thoroughly characterized than SpyCas9. A previous report used PCR 400 
amplification and high-throughput sequencing to detect the frequencies of lesions at 15-20 predicted 401 
NmeCas9 off-target sites for each of three guides in human cells, and found only background levels of 402 
indels in all cases, suggesting a very high degree of precision for NmeCas9 [54]. However, this report 403 
restricted its analysis to candidate sites with N4GNTT PAMs and three or fewer mismatches (or two 404 
mismatches combined with a 1-nt bulge) in the PAM-proximal 19 nucleotides, leaving open the possibility 405 
that legitimate off-target sites that did not fit these specific criteria remained unexamined. Accordingly, 406 
empirical and minimally-biased off-target profiles have never been generated for any NmeCas9/sgRNA 407 
combination, and the true off-target propensity of NmeCas9 therefore remains unknown. At the time we 408 
began this work, multiple methods for prediction-independent detection of off-target sites had been 409 
reported including GUIDE-seq, BLESS, Digenome-Seq, HTGTS, and IDLV capture, each with their 410 
own advantages and disadvantages (reviewed in [31, 34, 35]); additional methods (SITE-Seq [64], 411 
CIRCLE-seq [77], and BLISS [78]) have been reported more recently. Initially we chose to apply 412 
GUIDE-seq [63], which takes advantage of oligonucleotide incorporation into double-strand break sites, 413 
for defining the off-target profiles of both SpyCas9 and NmeCas9 when each is programmed to edit the 414 
DTS3, DTS7 and DTS8 sites (Fig. 4C-D) in the human genome. 415 
After confirming that the co-transfected double-stranded oligodeoxynucleotide (dsODN) was 416 
incorporated efficiently at the DTS3, DTS7 and DTS8 sites during both NmeCas9 and SpyCas9 editing 417 
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(Supplemental Fig. 4C), we then prepared GUIDE-seq libraries for each of the six editing conditions, as 418 
well as for the negative control conditions (i.e., in the absence of any sgRNA) for both Cas9 orthologs. 419 
The GUIDE-seq libraries were then subjected to high-throughput sequencing, mapped, and analyzed as 420 
described [79] (Fig. 5B-C). On-target editing with these guides was readily detected by this method, with 421 
the number of independent reads ranging from a low of 167 (NmeCas9, DTS8) to a high of 1,834 422 
(NmeCas9, DTS3) (Fig. 5C and Supplemental Table 2).  423 
For our initial analyses, we scored candidate sites as true off-targets if they yielded two or more 424 
independent reads and had six or fewer mismatches with the guide, with no constraints placed on the 425 
PAM match at that site. For SpyCas9, two of the sgRNAs (targeting DTS3 and DTS7) induced 426 
substantial numbers of off-target editing events (271 and 54 off-target sites, respectively (Fig. 5B)) under 427 
these criteria. The majority of these SpyCas9 off-target sites (88% and 77% for DTS3 and DTS7, 428 
respectively) were associated with a canonical NGG PAM. Reads were very abundant at many of these 429 
loci, and at five off-target sites (all with the DTS3 sgRNA) even exceeded the number of on-target reads 430 
(Fig. 5C). SpyCas9 was much more precise with the DTS8 sgRNA: we detected a single off-target site 431 
with five mismatches and an NGG PAM, and it was associated with only three independent reads, far 432 
lower than the 415 reads that we detected at the on-target site (Fig. 5C and Supplemental Table 2). 433 
Overall, the range of editing accuracies that we measured empirically for SpyCas9 – very high (e.g. 434 
DTS8), intermediate (e.g. DTS7), and poor (e.g. DTS3) – are consistent with the observations of other 435 
reports using distinct guides (reviewed in [31, 34, 35]). 436 
In striking contrast, GUIDE-seq analyses with NmeCas9, programmed with sgRNAs targeting 437 
the exact same three sites, yielded off-target profiles that were exceptionally specific in all cases (Fig. 5B-438 
C). For DTS3 and DTS8 we found no reads at any site with six or fewer guide mismatches; for DTS7 we 439 
found one off-target site with four mismatches (three of which were at the PAM-distal end; see 440 
Supplemental Table 2), and even at this site there were only 12 independent reads, ~100x fewer than the 441 
1,222 reads detected at DTS7 itself. This off-target site was also associated with a PAM (N4GGCT) that 442 
would be expected to be poorly functional, though it could also be considered a “slipped” PAM with a 443 
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more optimal consensus but variant spacing (N5GCTT). Purified, recombinant NmeCas9 has been 444 
observed to catalyze DNA cleavage in vitro at a site with a similarly slipped PAM [52]. To explore the off-445 
targeting potential of NmeCas9 further, we decreased the stringency of our mapping to allow detection of 446 
off-target sites with up to 10 mismatches. Even in these conditions, only four (DTS7), 15 (DTS8), and 16 447 
(DTS3) candidate sites were identified, most of which had only four or fewer reads (Fig. 5C) and were 448 
associated with poorly functional PAMs (Supplemental Table 2). We consider it likely that most if not all 449 
of these low-probability candidate off-target sites represent background noise caused by spurious priming 450 
and other sources of experimental error. 451 
As an additional test of off-targeting potential, we repeated the DTS7 GUIDE-seq experiments 452 
with both SpyCas9 and NmeCas9, but this time using a different transfection reagent (Lipofectamine3000 453 
rather than Polyfect). These repeat experiments revealed that >96% (29 out of 30) of off-target sites with 454 
up to five mismatches were detected under both transfection conditions for SpyCas9 (Supplemental Table 455 
1). However, the NmeCas9 GUIDE-seq data showed no overlap between the potential sites identified 456 
under the two conditions, again suggesting that the few off-target reads that we did observe are unlikely to 457 
represent legitimate off-target editing sites.  458 
To confirm the validity of the off-target sites defined by GUIDE-seq, we designed primers 459 
flanking candidate off-target sites identified by GUIDE-seq, PCR-amplified those loci following standard 460 
genome editing (i.e., in the absence of co-transfected GUIDE-seq dsODN) (3 biological replicates), and 461 
then subjected the PCR products to high-throughput sequencing to detect the frequencies of Cas9-462 
induced indels. For this analysis we chose the top candidate off-target sites (as defined by GUIDE-seq read 463 
count) for each of the six cases (DTS3, DTS7 and DTS8, each edited by either SpyCas9 or NmeCas9). In 464 
addition, due to the low numbers of off-target sites and the low off-target read counts observed during the 465 
NmeCas9 GUIDE-seq experiments, we analyzed the top two predicted off-target sites for the three 466 
NmeCas9 sgRNAs, as identified by CRISPRseek (Fig. 5A and Table 2) [76]. On-target indel formation 467 
was detected in all cases, with editing efficiencies ranging from 7% (DTS8, with both SpyCas9 and 468 
NmeCas9) to 39% (DTS3 with NmeCas9) (Fig. 5D). At the off-target sites, our targeted deep-sequencing 469 
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analyses largely confirmed our GUIDE-seq results: SpyCas9 readily induced indels at most of the tested 470 
off-target sites when paired with the DTS3 and DTS7 sgRNAs, and in some cases the off-target editing 471 
efficiencies approached those observed at the on-target sites (Fig. 5D). Although some SpyCas9 off-472 
targeting could also be detected with the DTS8 sgRNA, the frequencies were much lower (<0.1% in all 473 
cases). Off-target lesions induced by NmeCas9 were far less frequent in all cases, even with the DTS3 474 
sgRNA that was so efficient at on-target mutagenesis: many off-target sites exhibited lesion efficiencies 475 
that were indistinguishable from background, and never rose above ~0.02% (Fig. 5D). These results, in 476 
combination with the GUIDE-seq analyses described above, reveal wild-type NmeCas9 to be an 477 
exceptionally precise genome editing enzyme. 478 
 To explore NmeCas9 editing accuracy more deeply, we chose 16 additional NmeCas9 target sites 479 
across the genome, 10 with canonical N4GATT PAMs and six with variant functional PAMs 480 
(Supplemental Table 9). We then performed GUIDE-seq and analyses of NmeCas9 editing at these sites. 481 
GUIDE-seq analysis readily revealed editing at each of these sites, with on-target read counts ranging 482 
from ~100 to ~5,000 reads (Fig. 6A). More notably, off-target reads were undetectable by GUIDE-seq 483 
with 14 out of the 16 sgRNAs (Fig. 6B). Targeted deep sequencing of PCR amplicons, which is a more 484 
quantitative readout of editing efficiency than either GUIDE-seq or T7E1 analysis, confirmed on-target 485 
editing in all cases, with indel efficiencies ranging from ~5-85% (Fig. 6C).  486 
The two guides with off-target activity (NTS1C and NTS25) had only two and one off-target sites, 487 
respectively (Fig. 6B and Supplemental Fig. 5). Off-target editing was confirmed by high-throughput 488 
sequencing and analysis of indels (Fig. 6D). Compared with the on-target site (perfectly matched at all 489 
positions other than the 5’-terminal guide nucleotide, and with an optimal N4GATT PAM), the efficiently 490 
targeted NTS1C-OT1 had two wobble pairs and one mismatch (all in the nine PAM-distal nucleotides), 491 
as well as a canonical N4GATT PAM (Fig. 6E and Supplemental Table 2). The weakly edited NTS1C-492 
OT2 site had only a single mismatch (at the 11th nucleotide, counting in the PAM-distal direction), but 493 
was associated with a non-canonical N4GGTT (or a “slipped” N5GTTT) PAM (Fig. 6E and 494 
Supplemental Table 2). NTS25 with an N4GATA PAM was the other guide with a single off-target site 495 
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(NTS25-OT1), where NmeCas9 cleaved and edited up to ~1,000x less efficiently than at the on-target site 496 
(Fig. 6D). This minimal amount of off-target editing arose despite the association of NTS25-OT1 with an 497 
optimal N4GATT PAM, unlike the variant N4GATA PAM that flanks the on-target site. Overall, our 498 
GUIDE-seq and sequencing-based analyses demonstrate that NmeCas9 genome editing is exceptionally 499 
accurate: we detected and confirmed cellular off-target editing with only two of the 19 guides tested, and 500 
even in those two cases, only one or two off-target sites could be found for each. Furthermore, of the three 501 
bona fide off-target sites that we identified, only one generated indels at substantial frequency (11.6%); 502 
indel frequencies were very modest (0.3% or lower) at the other two off-target sites.   503 
We next sought to corroborate and expand on our GUIDE-seq results with a second prediction-504 
independent method.  We applied the SITE-SeqTM (Caribou Biosciences, Inc., Berkeley, CA) assay, a 505 
biochemical-based method that does not rely on cellular events such as DNA repair, thus potentially 506 
enabling a more thorough profiling of genome-wide specificity [63]. SITE-Seq libraries were prepared for 507 
the three dual target sites with both Cas9 orthologues as well as for twelve of the NmeCas9-only target 508 
sites.  SITE-Seq was performed on HEK293T genomic DNA (gDNA) treated with a range of RNP 509 
concentrations (4 nM – 256 nM) previously shown to discriminate high and low probability cellular off-510 
targets [63].  Finally, the resulting libraries were sequenced, aligned, and then analyzed as previously 511 
described [63].  512 
Negative controls without RNP recovered zero sites across any concentrations, whereas SpyCas9 513 
assembled with sgRNAs targeting DTS3, DTS7, or DTS8 recovered hundreds (at 4 nM RNP) to 514 
thousands (at 256 nM RNP) of biochemical off-target sites (Fig. 6F).  In contrast, NmeCas9 assembled 515 
with sgRNAs targeting the same three sites recovered only their on-target sites at 4 nM RNP and at most 516 
29 off-target sites at 256 nM RNP (Fig. 6F).  Moreover, the 12 additional NmeCas9 target sites showed 517 
similarly high specificity: eight samples recovered only the on-target sites at 4 nM RNP and six of those 518 
recovered no more than nine off-targets at 256 nM RNP (Supplemental Fig. 6A).  Across NmeCas9 519 
RNPs, off-target sequence mismatches appeared enriched in the 5’ end of the sgRNA target sequence 520 
(Supplemental Table 4).  Finally, three of the NmeCas9 RNPs (NTS30, NTS4C, and NTS59) required 521 
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elevated concentrations to retrieve their on-targets, potentially due to poor sgRNA transcription and/or 522 
RNP assembly.  These RNPs were therefore excluded from further analysis.  523 
We next performed cell-based validation experiments to investigate whether any of the 524 
biochemical off-targets were edited in cells. Since NmeCas9 recovered only ~100 biochemical off-targets 525 
across all RNPs and concentrations, we could examine each site for editing in cells.  SpyCas9 generated 526 
>10,000 biochemical off-targets across all DTS samples, preventing comprehensive cellular profiling.  527 
Therefore, for each RNP we selected 96 of the high cleavage sensitivity SITE-Seq sites (i.e., recovered at 528 
all concentrations tested in SITE-Seq) for examination, as we predicted those were more likely to 529 
accumulate edits in cells [63] (Supplemental Table 5).  Sites were randomly selected within this cohort 530 
and only included a subset of the GUIDE-seq validation test set sites (1/8 and 5/8 overlapping sites for 531 
DTS3 and DTS7, respectively).   Additionally, SITE-Seq and GUIDE-seq validations were performed on 532 
the same gDNA samples to facilitate comparisons between data sets.  533 
Across all NmeCas9 RNPs, only three cellular off-targets were observed.  These three all 534 
belonged to the NTS1C RNP, and two of them had also been detected with GUIDE-seq.  Of note, all 535 
high cleavage sensitivity SITE-Seq sites (i.e., all on-targets and the single prominent NTS1C off-target, 536 
NTS1C-OT1) showed editing in cells.  Conversely, SITE-Seq sites with low cleavage sensitivity, defined 537 
as being recovered at only 64 nM and/or 256 nM RNP, were rarely found as edited (2/93 sites).  538 
Importantly, this suggests that we identified all or the clear majority of NmeCas9 cellular off-targets, albeit 539 
at our limit of detection.  Across all SpyCas9 RNPs, 14 cellular off-targets were observed (8/70 sites for 540 
DTS3, 6/83 sites for DTS7, and 0/79 sites for DTS8) (Supplemental Table 5).  Since our data set was 541 
only a subset of the total number of high cleavage sensitivity SITE-Seq sites, and excluded many of the 542 
GUIDE-seq validated sites, we expect that sequencing all SITE-Seq sites would uncover additional 543 
cellular off-targets. Taken together, these data corroborate our GUIDE-seq results, suggesting that 544 
NmeCas9 can serve as a highly specific genome editing platform.   545 
 546 
Indel spectrum at NmeCas9-edited sites 547 
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 Our targeted deep sequencing data at the three dual target sites (Fig. 5D, Supplemental Fig. 4A 548 
and Supplemental Table 5) enabled us to analyze the spectrum of insertions and deletions generated by 549 
NmeCas9, in comparison with those of SpyCas9 when editing the exact same sites (Supplemental Figs. 6B 550 
and 7-9). Although small deletions predominated at all three sites with both Cas9 orthologs, the frequency 551 
of insertions was lower for NmeCas9 than it was with SpyCas9 (Supplemental Figs. 6B and 7-9). For both 552 
SpyCas9 and NmeCas9, the vast majority of insertions were only a single nucleotide (Supplemental Fig. 553 
8). The sizes of the deletions varied from one target site to the other for both Cas9 orthologs. Our data 554 
suggest that at Cas9 edits, deletions predominated over insertions and the indel size varies considerably 555 
site to site (Supplemental Figs. 6B, 10 and 11). 556 
 557 
Truncated sgRNAs reduce off-target cleavage by NmeCas9 558 
Although NmeCas9 exhibits very little propensity to edit off-target sites, for therapeutic 559 
applications it may be desirable to suppress even the small amount of off-targeting that occurs (Fig. 6). 560 
Several strategies have been developed to suppress off-targeting by SpyCas9 [31, 34, 35], some of which 561 
could be readily applied to other orthologs. For example, truncated sgRNAs (tru-sgRNAs) sometimes 562 
suppress off-target SpyCas9 editing more than they suppress on-target editing [69]. Because 5’-terminal 563 
truncations are compatible with NmeCas9 function (Fig. 2), we tested whether NmeCas9 tru-sgRNAs can 564 
have similar suppressive effects on off-target editing without sacrificing on-target editing efficiency. 565 
First, we tested whether guide truncation can lead to NmeCas9 editing at novel off-target sites (i.e. 566 
at off-target sites not edited by full-length guides), as reported previously for SpyCas9 [69]. Our earlier 567 
tests of NmeCas9 on-target editing with tru-sgRNAs used guides targeting the NTS33 (Fig. 2B-C) and 568 
NTS32 (Fig. 2D-E) sites. GUIDE-seq did not detect any NmeCas9 off-target sites during editing with full-569 
length NTS32 and NTS33 sgRNAs (Fig. 6). We again used GUIDE-seq with a subset of the validated 570 
NTS32 and NTS33 tru-sgRNAs to determine whether NmeCas9 guide truncation leads to off-target 571 
editing at new sites, and found none (Supplemental Fig. 12). Although we cannot rule out the possibility 572 
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that other NmeCas9 guides could be identified that yield novel off-target events upon truncation, our 573 
results suggest that de novo off-targeting by NmeCas9 tru-sgRNAs is unlikely to be a pervasive problem.      574 
The most efficiently edited off-target site from our previous analyses was NTS1C-OT1, providing 575 
us with our most stringent test of off-target suppression. When targeted by the NTS1C sgRNA, NTS1C-576 
OT1 has one rG-dT wobble pair at position -16 (i.e., at the 16th base pair from the PAM-proximal end of 577 
the R-loop), one rC-dC mismatch at position -19, and one rU-dG wobble pair at position -23 (Fig. 6E). 578 
We generated a series of NTS1C-targeting sgRNAs with a single 5’-terminal G (for U6 promoter 579 
transcription) and spacer complementarities ranging from 24 to 15 nucleotides (GN24 to GN15, 580 
Supplemental Fig. 13A, top panel). Conversely, we designed a similar series of sgRNAs with perfect 581 
complementarity to NTS1C-OT1 (Supplemental Fig. 13B, top panel). Consistent with our earlier results 582 
with other target sites (Fig. 2), T7E1 analyses revealed that both sets of guides enabled editing of the 583 
perfectly-matched on-target site with truncations down to 19 nucleotides (GN18), but that shorter guides 584 
were inactive. On-target editing efficiencies at both sites were comparable across the seven active guide 585 
lengths (GN24 through GN18), with the exception of slightly lower efficiencies with the GN19 guides 586 
(Supplemental Fig. 13A & B, middle and bottom panels). 587 
 We then used targeted deep sequencing to test whether off-target editing is reduced with the 588 
truncated sgRNAs. With both sets of sgRNAs (perfectly complementary to either NTS1C or NTS1C-589 
OT1), we found that off-targeting at the corresponding near-cognate site persisted with the four longest 590 
guides (GN24, GN23, GN22, GN21; Fig. 7). However, off-targeting was abolished with the GN20 guide,  591 
without any significant reduction in on-target editing efficiencies (Fig. 7). Off-targeting was also absent 592 
with the GN19 guide, though on-target editing efficiency was compromised. These results, albeit from a 593 
limited data set, indicate that truncated sgRNAs (especially those with 20 or 19 base pairs of guide/target 594 
complementarity, 4-5 base pairs fewer than the natural length) can suppress even the limited degree of off-595 
targeting that occurs with NmeCas9.    596 
Unexpectedly, even though off-targeting at NTS1C-OT1 was abolished with the GN20 and GN19 597 
truncated NTS1C sgRNAs, truncating by an additional nucleotide (to generate the GN18 sgRNA) once 598 
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again yielded NTS1C-OT1 edits (Fig. 7A). This could be explained by the extra G residue at the 5’-599 
terminus of each sgRNA in the truncation series (Supplemental Fig. 13). With the NTS1C GN19 sgRNA, 600 
both the 5’-terminal G residue and the adjacent C residue are mismatched with the NTS1C-OT1 site. In 601 
contrast, with the GN18 sgRNA, the 5’-terminal G is complementary to the off-target site. In other words, 602 
with the NTS1C GN19 and GN18 sgRNAs, the NTS1C-OT1 off-target interactions (which are identical in 603 
the PAM-proximal 17 nucleotides) include two additional nucleotides of non-complementarity or one 604 
additional nucleotide of complementarity, respectively. Thus, the more extensively truncated GN18 605 
sgRNA has greater complementarity with the NTS1C-OT1 site than the GN19 sgRNA, explaining the re-606 
emergence of off-target editing with the former. This observation highlights the fact that the inclusion of a 607 
5’-terminal G residue that is mismatched with the on-target site, but that is complementary to a C residue 608 
at an off-target site, can limit the effectiveness of a truncated guide at suppressing off-target editing, 609 
necessitating care in truncated sgRNA design when the sgRNA is generated by cellular transcription. This 610 
issue is not a concern with sgRNAs that are generated by other means (e.g. chemical synthesis) that do not 611 
require a 5’-terminal G. Overall, our results demonstrate that NmeCas9 genome editing is exceptionally 612 
precise, and even when rare off-target editing events occur, tru-sgRNAs can provide a simple and effective 613 
way to suppress them.   614 
 615 
DISCUSSION 616 
The ability to use Type II and Type V CRISPR-Cas systems as RNA-programmable DNA-617 
cleaving systems [13, 14, 27] is revolutionizing many aspects of the life sciences, and holds similar promise 618 
for biotechnological, agricultural, and clinical applications. Most applications reported thus far have used 619 
a single Cas9 ortholog (SpyCas9). Thousands of additional Cas9 orthologs have also been identified [28], 620 
but only a few have been characterized, validated for genome engineering applications, or both. Adding 621 
additional orthologs promises to increase the number of targetable sites (through new PAM specificities), 622 
extend multiplexing possibilities (for pairwise combinations of Cas9 orthologs with orthogonal guides), and 623 
improve deliverability (for the more compact Cas9 orthologs). In addition, some Cas9s may show 624 
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mechanistic distinctions (such as staggered vs. blunt dsDNA breaks) [80], greater protein stability in vivo, 625 
improved control mechanisms (e.g. via multiple anti-CRISPRs that act at various stages of the DNA 626 
cleavage pathway) [57, 58, 60, 61, 81-83], and other enhancements. Finally, some may exhibit a greater 627 
natural propensity to distinguish between on- vs. off-target sites during genome editing applications, 628 
obviating the need for extensive engineering (as was necessary with SpyCas9) to attain the accuracy 629 
needed for many applications, especially therapeutic development. 630 
Here we have further defined the properties of NmeCas9 during editing in human cells, including 631 
validation and extension of previous analyses of guide length and PAM requirements [46, 53, 54]. 632 
Intriguingly, the tolerance to deviations from the N4G(A/C)TT natural PAM consensus [51] observed in 633 
vitro and in bacterial cells [46, 52] is considerably reduced in the mammalian context, i.e. fewer PAM 634 
variations are permitted during mammalian editing. The basis for this context-dependent difference is not 635 
clear but may be due in part to the ability to access targets within eukaryotic chromatin, or to decreased 636 
expression levels relative to potential DNA substrates, since lower SpyCas9/sgRNA concentrations have 637 
been shown to improve accuracy [30, 84, 85]. We have also found that steady-state NmeCas9 levels in 638 
human cells are markedly increased in the presence of its cognate sgRNA, suggesting that sgRNA-loaded 639 
NmeCas9 is more stable than apo NmeCas9. An increased proteolytic sensitivity of apo Cas9 relative to the 640 
sgRNA-bound form has been noted previously for a different Type II-C ortholog (Corynebacterium diphtheria 641 
Cas9, CdiCas9 [55]).   642 
A previous report indicated that NmeCas9 has high intrinsic accuracy, based on analyses of 643 
candidate off-target sites that were predicted bioinformatically [54]. However, the true genome-wide 644 
accuracy of NmeCas9 was not assessed empirically, as is necessary given well-established imperfections in 645 
bioinformatic predictions of off-targeting [31, 34, 35]. We have used GUIDE-seq [63] and SITE-Seq [64] 646 
to define the genome-wide accuracy of wild-type NmeCas9, including side-by-side comparisons with 647 
wildtype SpyCas9 during editing of identical on-target sites. We find that NmeCas9 is a consistently high-648 
accuracy genome editor, with off-target editing undetectable above background with 17 out of 19 649 
analyzed sgRNAs, and only one or three verified off-target edits with the remaining two guides. We 650 
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observed this exquisite specificity by NmeCas9 even with sgRNAs that target sites (DTS3 and DTS7 (see 651 
Fig. 5)) that are highly prone to off-target editing when targeted with SpyCas9. Of the four off-target sites 652 
that we validated, three accumulated <1% indels. Even with the one sgRNA that yielded a significant 653 
frequency of off-target editing (NTS1C, which induced indels at NTS1C-OT1 with approximately half 654 
the efficiency of on-target editing), the off-targeting with wild-type NmeCas9 could be easily suppressed 655 
with truncated sgRNAs. Our ability to detect NTS25-OT1 editing with GUIDE-seq, despite its very low 656 
(0.06%) editing efficiency based on high-throughput sequencing, indicates that our GUIDE-seq 657 
experiments can identify even very low-efficiency off-target editing sites. Similar considerations apply to 658 
our SITE-Seq analyses. We observed high accuracy even when NmeCas9 is delivered by plasmid 659 
transfection, a delivery method that is associated with higher off-target editing than more transient 660 
delivery modes such as RNP delivery [86, 87]. 661 
The two Type II-C Cas9 orthologs (NmeCas9 and CjeCas9) that have been validated for 662 
mammalian genome editing and assessed for genome-wide specificity [47, 54] (this work) have both 663 
proven to be naturally hyper-accurate. Both use longer guide sequences than the 20-nucleotide guides 664 
employed by SpyCas9, and both also have longer and more restrictive PAM requirements. For both Type 665 
II-C orthologs, it is not yet known whether the longer PAMs, longer guides, or both account for the 666 
limited off-target editing. Type II-C Cas9 orthologs generally cleave dsDNA more slowly than SpyCas9 667 
[49, 55], and it has been noted that lowering kcat can, in some circumstances, enhance specificity [88]. 668 
Whatever the mechanistic basis for the high intrinsic accuracy, it is noteworthy that it is a property of the 669 
native proteins, without a requirement for extensive engineering. This adds to the motivation to identify 670 
more Cas9 orthologs with human genome editing activity, as it suggests that it may be unnecessary in 671 
many cases (perhaps especially among Type II-C enzymes) to invest heavily in structural and mechanistic 672 
analyses and engineering efforts to attain sufficient accuracy for many applications and with many desired 673 
guides, as was done with (for example) SpyCas9 [32, 33, 37, 38, 65]. Although Cas9 orthologs with more 674 
restrictive PAM requirements (such as NmeCas9, CjeCas9, and GeoCas9) by definition will afford lower 675 
densities of potential target sites than SpyCas9 (which also usually affords the highest on-target editing 676 
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efficiencies among established Cas9 orthologs), the combined targeting possibilities for multiple such 677 
Cas9s will increase the targeting options available within a desired sequence window, with little propensity 678 
for off-targeting. The continued exploration of natural Cas9 variation, especially for those orthologs with 679 
other advantages such as small size and anti-CRISPR off-switch control, therefore has great potential to 680 
advance the CRISPR genome editing revolution.  681 
 682 
CONCLUSIONS 683 
NmeCas9 is an intrinsically high-accuracy genome editing enzyme in mammalian cells, and the limited 684 
off-target editing that occurs can (at least in some cases) be suppressed by guide truncation. Continued 685 
exploration of Cas9 orthologs could therefore yield additional enzymes that do not require extensive 686 
characterization and engineering to prevent off-target editing.  687 
 688 
METHODS 689 
Plasmids 690 
Two plasmids for the expression of NmeCas9 were used in this study. The first construct (used in Figs. 1 691 
and 2) was derived from the plasmid pSimpleII where NmeCas9 was cloned under the control of the 692 
elongation factor-1α promoter, as described previously [53]. The Cas9 gene in this construct expresses a 693 
protein with two NLSs and an HA tag. To make an all-in-one expression plasmid, a fragment containing 694 
a BsmBI-crRNA cassette linked to the tracrRNA by six nucleotides, under the control of U6 RNA 695 
polymerase III promoter, was synthesized as a gene block (Integrated DNA Technologies) and inserted 696 
into pSimpleII, generating the pSimpleII-Cas9-sgRNA-BsmBI plasmid that includes all elements needed 697 
for editing. To insert specific spacer sequence into the crRNA cassette, synthetic oligonucleotides were 698 
annealed to generate a duplex with overhangs compatible with those generated by BsmBI digestion of the 699 
pSimpleII-Cas9-sgRNA-BsmBI plasmid. The insert was then ligated into the BsmBI-digested plasmid. For 700 
Figs. 3-7, NmeCas9 and SpyCas9 constructs were expressed from the pCS2-Dest Gateway plasmid under 701 
the control of the CMV IE94 promoter [89]. All sgRNAs used with pCS2-Dest-Cas9 were driven by the 702 
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U6 promoter in pLKO.1-puro [90]. The M427 GFP reporter plasmid [66] was used as described [65].  703 
 704 
Cell culture, transfection, and transduction 705 
HEK293T were cultured in DMEM with 10% FBS and 1% Penicillin/Streptomycin (Gibco) in a 37°C 706 
incubator with 5% CO2. K562 cells were grown in the same conditions but using IMDM. HFF cells were 707 
grown in the same conditions but using DMEM with Glutamax and 20% FBS without antibiotics. mESCs 708 
were grown in DMEM supplemented with 10% FBS, glutamine beta-ME and LIF. For transient 709 
transfection, we used early to mid-passage cells (passage number 4-18). Approximately 1.5 x 105 cells were 710 
transfected with 150 ng Cas9-expressing plasmid, 150 ng sgRNA-expressing plasmid and 10 ng mCherry 711 
plasmid using Polyfect transfection reagent (Qiagen) in a 24-well plate according to the manufacturer’s 712 
protocol. For the GFP reporter assay, 100 ng M427 plasmid was included in the co-transfection mix. 713 
Transduction was done as described previously [91].   714 
 715 
Western blotting 716 
48 h after transfection, cells were harvested and lysed with 50 μl of RIPA buffer. Protein concentration 717 
was determined with the BCA kit (Thermo Scientific) and 12 μg of proteins were used for electrophoresis 718 
and blotting. The blots were probed with anti-HA (Sigma, H3663) and anti-GAPDH (Abcam, ab9485) as 719 
primary antibodies, and then with horseradish peroxidase–conjugated anti-mouse IgG (Thermoscientific, 720 
62-6520) or anti-rabbit IgG (Biorad, 1706515) secondary antibodies, respectively. Blots were visualized 721 
using the Clarity Western ECL substrate (Biorad, 170-5060). 722 
Flow cytometry 723 
The GFP reporter was used as described previously [65]. Briefly, cells were harvested 48 hours after 724 
transfection and used for FACS analysis (BD Accuri 6C). To minimize the effects of differences in the 725 
efficiency of transfection among samples, cells were initially gated for mCherry-expression, and the 726 
percentage of GFP-expressing cells were quantified within mCherry positive cells. All experiments were 727 
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performed in triplicate with data reported as mean values with error bars indicating the standard error of 728 
the mean (s.e.m.). 729 
Genome editing 730 
72 hours after transfection, genomic DNA was extracted via the DNeasy Blood and Tissue kit (Qiagen), 731 
according to the manufacturer’s protocol. 50 ng DNA was used for PCR-amplification using primers 732 
specific for each genomic site (Supplemental Table 9) with High Fidelity 2X PCR Master Mix (New 733 
England Biolabs). For T7E1 analysis, 10 μl of PCR product was hybridized and treated with 0.5 μl T7 734 
Endonuclease I (10 U/μl, New England Biolabs) in 1X NEB Buffer 2 for 1 hour. Samples were run on a 735 
2.5% agarose gel, stained with SYBR-safe (ThermoFisher Scientific), and quantified using the 736 
ImageMaster-TotalLab program. Indel percentages are calculated as previously described [92, 93]. 737 
Experiments for T7E1 analysis are performed in triplicate with data reported as mean ± s.e.m. For indel 738 
analysis by TIDE, 20 ng of PCR product is purified and then sequenced by Sanger sequencing. The trace 739 
files were subjected to analysis using the TIDE web tool (https://tide.deskgen.com). 740 
 741 
Expression and purification of NmeCas9 742 
NmeCas9 was cloned into the pMCSG7 vector containing a T7 promoter followed by a 6xHis tag and a 743 
tobacco etch virus (TEV) protease cleavage site. Two NLSs on the C-terminus of NmeCas9 and another 744 
NLS on the N-terminus were also incorporated. This construct was transformed into the Rosetta 2 DE3 745 
strain of E. coli. Expression of NmeCas9 was performed as previously described for SpyCas9 [14]. Briefly, 746 
a bacterial culture was grown at 37°C until an OD600 of 0.6 was reached. At this point the temperature 747 
was lowered to 18°C followed by addition of 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) to 748 
induce protein expression. Cells were grown overnight, and then harvested for purification. Purification of 749 
NmeCas9 was performed in three steps: Nickel affinity chromatography, cation exchange 750 
chromatography, and size exclusion chromatography. The detailed protocols for these can be found in 751 
[14]. 752 
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 753 
RNP delivery of NmeCas9 754 
RNP delivery of NmeCas9 was performed using the Neon transfection system (ThermoFisher). 755 
Approximately 40 picomoles of NmeCas9 and 50 picomoles of sgRNA were mixed in buffer R and 756 
incubated at room temperature for 30 minutes. This preassembled complex was then mixed with 50,000 – 757 
150,000 cells, and electroporated using 10 µL Neon tips. After electroporation, cells were plated in pre-758 
warmed 24-well plates containing the appropriate culture media without antibiotics. The number of cells 759 
used and pulse parameters of electroporation were different for different cell types tested. The number of 760 
cells used were 50,000, 100,000, and 150,000 for PLB985 cells, HEK293T cells, and K562/HFF cells 761 
respectively. Electroporation parameters (voltage, width, number of pulses) were 1150 v, 20 ms, 2 pulses 762 
for HEK293T cells; 1000 v, 50 ms, 1 pulse for K562 cells; 1350 v, 35 ms, 1 pulse for PLB985 cells; and 763 
1700 v, 20 ms, 1pulse for HFF cells. 764 
 765 
γH2AX immunofluorescence staining and flow cytometry 766 
For immunofluorescence, mouse embryonic stem cells (mESCs) were crosslinked with 4% 767 
paraformaldehyde and stained with anti-γH2AX (LP BIO, AR-0149-200) as primary antibody and Alexa 768 
Fluor® 488 goat anti-rabbit IgG (Invitrogen, A11034) as secondary antibody. DNA was stained with 769 
DAPI. For a positive control, E14 cells were irradiated with 254 nm UV light (3 mJ/cm2). Images were 770 
taken by a Nikon Eclipse E400 and representative examples were chosen. 771 
For flow cytometry, cells were fixed with 70% ethanol, primary and secondary antibody were as 772 
described above for immunofluorescence, and DNA was stained with propidium iodide. Cells were 773 
analyzed by BD FACSCalibur. The box plot was presented with the bottom line of the box representing 774 
the first quartile, the band inside box indicating the median, the top line being the third quartile, the 775 
bottom end of whisker denoting data of first quartile minus 1.5 times of interquartile range (no less than 776 
0), and the top end of the whisker indicating data of third quartile plus 1.5 times of interquartile. Outliers 777 
are not shown. All experiments were performed in duplicate. 778 
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 779 
CRISPRseek analysis of potential off-target sites 780 
Global off-target analyses for DTS3, DTS7, and DTS8 with NmeCas9 sgRNAs were performed using the 781 
Bioconductor package CRISPRseek 1.9.1 [76] with parameter settings tailored for NmeCas9. Specifically, 782 
all parameters are set as default except the following: gRNA.size = 24, PAM = "NNNNGATT", 783 
PAM.size = 8, RNA.PAM.pattern = "NNNNGNNN$", weights = c(0, 0, 0, 0, 0, 0, 0.014, 0, 0, 0.395, 784 
0.317, 0, 0.389, 0.079, 0.445, 0.508, 0.613, 0.851, 0.732, 0.828, 0.615, 0.804, 0.685, 0.583), 785 
max.mismatch = 6, allowed.mismatch.PAM = 7, topN = 10000, min.score = 0.   This setting means that 786 
all seven permissive PAM sequences (N4GATT, N4GCTT, N4GTTT, N4GACA, N4GACT, N4GATA, 787 
N4GTCT) were allowed and all off-targets with up to 6 mismatches were collected [the sgRNA length was 788 
changed from 20 to 24; four additional zeros were added to the beginning of the weights series to be 789 
consistent with the gRNA length of 24; and topN (the number of off-target sites displayed) and min.score 790 
(the minimum score of an off-target to be included in the output) were modified to enable identification of 791 
all off-target sites with up to 6 mismatches]. Predicted off-target sites for DTS3, DTS7, and DTS8 with 792 
SpyCas9 sgRNAs were obtained using CRISPRseek 1.9.1 default settings for SpyCas9 (with NGG, NAG, 793 
and NGA PAMs allowed). Batch scripts for high-performance computing running the IBM LSF 794 
scheduling software are included in the supplemental section. Off-target sites were binned according to 795 
the number of mismatches relative to the on-target sequence. The numbers of off-targets for each sgRNA 796 
were counted and plotted as pie charts. 797 
 798 
GUIDE-seq 799 
We performed GUIDE-seq experiment with some modifications to the original protocol [63], as described 800 
[65]. Briefly, in 24-well format, HEK293T cells were transfected with 150 ng of Cas9, 150 ng of sgRNA, 801 
and 7.5 pmol of annealed GUIDE-seq oligonucleotide using Polyfect transfection reagent (Qiagen) for all 802 
six guides (DTS3, DTS7 and DTS8 for both the NmeCas9 and SpyCas9 systems). Experiments with 803 
DTS7 sgRNAs were repeated using Lipofectamine 3000 transfection reagent (Invitrogen) according to the 804 
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manufacturer’s protocol. 48 h after transfection, genomic DNA was extracted with a DNeasy Blood and 805 
Tissue kit (Qiagen) according to the manufacturer protocol. Library preparation, sequencing, and read 806 
analyses were done according to protocols described previously [63, 65]. Only sites that harbored a 807 
sequence with up to six or ten mismatches with the target site (for SpyCas9 or NmeCas9, respectively) 808 
were considered potential off-target sites. Data were analyzed using the Bioconductor package GUIDEseq 809 
version 1.1.17 (Zhu et al., 2017). For SpyCas9, default setting was used except that min.reads = 2, 810 
max.mismatch = 6, allowed.mismatch.PAM = 2, PAM.pattern = "NNN$", BSgenomeName = Hsapiens, 811 
txdb = TxDb.Hsapiens.UCSC.hg19.knownGene, orgAnn = org.Hs.egSYMBOL For NmeCas9, default 812 
setting was used except that PAM.size = 8, PAM = "NNNNGATT", min.reads = 2, 813 
allowed.mismatch.PAM = 4, PAM.pattern = "NNNNNNNN$", BSgenomeName = Hsapiens, txdb = 814 
TxDb.Hsapiens.UCSC.hg19.knownGene, orgAnn = org.Hs.egSYMBOL. NmeCas9 dataset was 815 
analyzed twice with max.mismatch = 6 and max.mismatch = 10 respectively. The gRNA.size was set to 816 
the length of the gRNA used, and various number of 0’s was added at the beginning of weights to make 817 
the length of weights equal to the gRNA size.  For example, for gRNA with length 24, weights = 818 
c(0,0,0,0,0, 0, 0.014, 0, 0, 0.395, 0.317, 0, 0.389, 0.079, 0.445, 0.508, 0.613, 0.851, 0.732, 0.828, 0.615, 819 
0.804, 0.685, 0.583)  (Zhu et al., 2017). These regions are reported in Supplemental Table 2. 820 
SITE-Seq  821 
We performed the SITE-Seq assay as described previously [63]. In 50 mL conical tubes, high molecular 822 
weight genomic DNA (gDNA) was extracted from HEK293T cells using the Blood and Cell Culture DNA 823 
Maxi Kit (Qiagen) according to the manufacturer’s protocol. sgRNAs for both NmeCas9 and SpyCas9 824 
RNP assembly were transcribed from PCR-assembled DNA templates containing T7 promoters.  Oligo 825 
sequences used in DNA template assembly can found be in Supplemental Table 8.  PCR reactions were 826 
performed using Q5 Hot Start High-Fidelity 2X Master Mix (New England Biolabs) with the following 827 
thermal cycling conditions: 98°C for 2 minutes, 30 cycles of 20 seconds at 98°C, 20 seconds at 52°C, 15 828 
seconds at 72°C, and a final extension at 72°C for 2 minutes. sgRNAs were in vitro transcribed using the 829 
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HiScribe T7 High Yield RNA Synthesis Kit (New England Biolabs) according to manufacturer’s protocol. 830 
Transcription reactions were digested with 2 units RNase-free DNase I (New England Biolabs) at 37°C 831 
for 10 min; the reaction was stopped by adding EDTA to a final concentration of 35 mM and incubating 832 
at 75°C for 10 min. All guides were purified with RNAClean beads (Beckman Coulter) and quantified 833 
with the Quant-IT Ribogreen RNA Assay kit (ThermoFisher) according to the manufacturers’ protocols.  834 
Individual RNPs were prepared by incubating each sgRNA at 95°C for 2 minutes, then allowed to slowly 835 
come to room temperature over 5 minutes. Each sgRNA was then combined with its respective Cas9 in a 836 
3:1 sgRNA:Cas9 molar ratio and incubated at 37°C for 10 minutes in cleavage reaction buffer (20 mM 837 
HEPES, pH 7.4, 150 mM KCl, 10 mM MgCl2, 5% glycerol). In 96-well format, 10 µg of gDNA was 838 
treated with 0.2 pmol, 0.8 pmol, 3.2 pmol, and 12.8 pmol of each RNP in 50 µL total volume in cleavage 839 
reaction buffer, in triplicate. Negative control reactions were assembled in parallel and did not include 840 
any RNP. gDNA was treated with RNPs for 4 hours at 37°C. Library preparation and sequencing were 841 
done according to protocols described previously [63] using the Illumina NextSeq platform, and ~3 842 
million reads were obtained for each sample.  Any SITE-Seq sites without off-target motifs located within 843 
1 nt of the cut-site were considered false-positives and discarded.        844 
 845 
Targeted deep sequencing analysis  846 
To measure indel frequencies, targeted deep sequencing analyses were done as previously described [65]. 847 
Briefly, we used two-step PCR amplification to produce DNA fragments for each on-target and off-target 848 
site. In the first step, we used locus-specific primers bearing universal overhangs with complementary ends 849 
to the TruSeq adaptor sequences (Supplemental Table 7). DNA was amplified with Phusion High Fidelity 850 
DNA Polymerase (New England Biolabs) using annealing temperatures of 60˚C, 64˚C or 68˚C, depending 851 
on the primer pair. In the second step, the purified PCR products were amplified with a universal forward 852 
primer and an indexed reverse primer to reconstitute the TruSeq adaptors (Supplemental Table 7). Input 853 
DNA was PCR-amplified with Phusion High Fidelity DNA Polymerase (98°C, 15s; 61°C, 25s; 72°C, 18s; 854 
9 cycles) and equal amounts of the products from each treatment group were mixed and run on a 2.5% 855 
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agarose gel. Full-size products (~250bp in length) were gel-extracted. The purified library was deep 856 
sequenced using a paired-end 150bp MiSeq run.  857 
MiSeq data analysis was performed using a suite of Unix-based software tools. First, the quality of 858 
paired-end sequencing reads (R1 and R2 fastq files) was assessed using FastQC 859 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Raw paired-end reads were combined 860 
using paired end read merger (PEAR) [94] to generate single merged high-quality full-length reads. Reads 861 
were then filtered by quality [using Filter FASTQ [95]] to remove those with a mean PHRED quality 862 
score under 30 and a minimum per base score under 24. Each group of reads was then aligned to a 863 
corresponding reference sequence using BWA (version 0.7.5) and SAMtools (version 0.1.19). To 864 
determine indel frequency, size and distribution, all edited reads from each experimental replicate were 865 
combined and aligned, as described above. Indel types and frequencies were then cataloged in a text 866 
output format at each base using bam-readcount (https://github.com/genome/bam-readcount). For each 867 
treatment group, the average background indel frequencies (based on indel type, position and frequency) 868 
of the triplicate negative control group were subtracted to obtain the nuclease-dependent indel 869 
frequencies. Indels at each base were marked, summarized and plotted using GraphPad Prism. Deep 870 
sequencing data and the results of statistical tests are reported in Supplemental Table 3.  871 
SITE-Seq cell-based validation was performed as previously described with minor modifications 872 
[63].  In brief, SITE-Seq sites were amplified from ~1,000-4,000 template copies per replicate and 873 
sequencing data from Cas9-treated samples were combined to minimize any variability due to uneven 874 
coverage across replicates.  Cas9 cleavage sites were registered from the SITE-Seq data, and mutant reads 875 
were defined as any non-reference variant calls within 20 bp of the cut site.  Sites with low sequencing 876 
coverage (< 1,000 reads in the combined, Cas9-treated samples or <200 reads in the reference samples) 877 
or >2% variant calls in the reference samples were discarded.  Sites were tallied as cellular off-targets if 878 
they accumulated > 0.5% mutant reads in the combined, Cas9-treated samples.  This threshold 879 
corresponded to sites that showed unambiguous editing when DNA repair patterns were visually 880 
inspected.     881 
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 882 
List of Abbreviations 883 
AAV: adeno-associated virus; 884 
BLESS: breaks labelling, enrichment on streptavidin and next-generation sequencing; 885 
BLISS: breaks labeling in situ and sequencing; 886 
bp: base pair; 887 
Cas: CRISPR-associated; 888 
Circle-seq: circularization for in vitro reporting of cleavage effects by sequencing; 889 
CjeCas9: Campylobacter jejuni Cas9; 890 
CMV: cytomegalovirus; 891 
CRISPR: clustered, regularly interspaced, short palindromic repeats; 892 
crRNAs: CRISPR RNAs; 893 
dCas9: “dead” Cas9; 894 
Digenome-seq: digested genome sequencing; 895 
DSB: double-strand breaks; 896 
dsODN: double-stranded oligodeoxynucleotide; 897 
DTS: dual target site; 898 
EF1α: elongation factor-1α; 899 
GeoCas9: Geobacillus stearothermophilus; 900 
GUIDE-seq: genome-wide unbiased identification of double strand breaks enabled by sequencing; 901 
HDR: homology-directed repair; 902 
HTGTS: high-throughput genome-wide translocation sequencing; 903 
IDLV: integrase-defective lentiviral vector; 904 
mESC: mouse embryonic stem cell; 905 
NHEJ: non-homologous end joining; 906 
NLS: nuclear localization signal;  907 
NmeCas9: Neisseria meningitidis (strain 8013) Cas9; 908 
NTS: NmeCas9 target site; 909 
PAM: protospacer adjacent motif; 910 
RNP: ribonucleoprotein; 911 
SauCas9: Staphylococcus aureus Cas9; 912 
sgRNA: single-guide RNA; 913 
SITE-Seq: selective enrichment and identification of tagged genomic DNA ends by sequencing; 914 
SpyCas9: Streptococcus pyogenes Cas9; 915 
T7E1: T7 Endonuclease 1; 916 
tracrRNA: trans-acting CRISPR RNA; 917 
tru-sgRNAs: truncated sgRNAs. 918 
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 1187 
Figures 1188 
 1189 
Figure 1. NmeCas9 expression and activity in human (HEK293T) cells. (A) Western blot detection of HA-tagged 1190 
NmeCas9 in transiently transfected HEK293T cells. Lane 1: Cells transfected with SpyCas9 plasmid under the 1191 
control of the CMV promoter. Lane 2: Cells transfected with NmeCas9 plasmid under the control of the elongation 1192 
factor-1α (EF1α) promoter. Lane 3: Cells expressing NmeCas9 and a non-targeting sgRNA (nt-sgRNA), which lacks 1193 
a complementary site in the human genome. Lane 4: Cells expressing NmeCas9 and a sgRNA targeting 1194 
chromosomal site NTS3. Upper panel: Anti-HA western blot. Lower panel: Anti-GAPDH western blot as a loading 1195 
control. (B) NmeCas9 targeting co-transfected split-GFP reporter with ps9, ps24 and ps25 sites. Plasmid cleavage by 1196 
SpyCas9 is used as a positive control, and a reporter without a guide-complementary site (No ps: no protospacer) is 1197 
used as a negative control to define background levels of recombination leading to GFP+ cells. (C) NmeCas9 1198 
programmed independently with different sgRNAs targeting eleven genomic sites flanked by an N4GATT PAM, 1199 
detected by T7E1 analysis. (D) Quantitation of editing efficiencies from three independent biological replicates 1200 
performed on different days. Error bars indicate ± standard error of the mean (± s.e.m.). (E) Genomic lesions with 1201 
NmeCas9 programmed independently with different guides in different cell lines and using different methods of 1202 
delivery. 1203 
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 1204 
Figure 2. NmeCas9 guide length requirements in mammalian cells. (A) Split-GFP activity profile of NmeCas9 1205 
cleavage with ps9 sgRNAs bearing spacers of varying lengths (18-24 nts) along with 5’-terminal G residues to enable 1206 
transcription. Bars represent mean values ± s.e.m. from three independent biological replicates performed on 1207 
different days. (B) T7EI analysis of editing efficiencies at the NTS33 genomic target site (with an N4GATT PAM) 1208 
with sgRNAs bearing spacers of varying lengths (13-25 nts) with 1-2 5’-terminal G residues. (C) Quantitation of 1209 
lesion efficiencies (of experiment in B) from three independent biological replicates performed on different days. 1210 
Error bars indicate ± standard error of the mean (± s.e.m.). (D) As in (B), but targeting the NTS32 genomic site (with 1211 
an N4GCTT PAM). (E) Quantitation of lesion efficiencies (of experiment in D) from three independent biological 1212 
replicates performed on different days. Error bars indicate ± standard error of the mean (± s.e.m.). 1213 
 1214 
Figure 3. Characterization of functional PAM sequences in human (HEK293T) cells. (A) Split-GFP activity profile 1215 
of NmeCas9 cleavage with ps9 sgRNA, with the target site flanked by different PAM sequences. Bars represent 1216 
mean values ± s.e.m. from three independent biological replicates performed on different days. (B) T7E1 analysis of 1217 
editing efficiencies at seven genomic sites flanked by PAM variants, as indicated. Products resulting from NmeCas9 1218 
genome editing are denoted by the red dots. (C) Quantitation of data from (B), as well as an additional site (NTS31; 1219 
N4GACA PAM) that was not successfully edited. Bars represent mean values ± s.e.m. from three independent 1220 
biological replicates performed on different days. 1221 
 1222 
Figure 4. NmeCas9 and SpyCas9 have comparable editing efficiencies in human (HEK293T) cells when targeting 1223 
the same chromosomal sites. (A)  Western blot analysis of NmeCas9 and SpyCas9. HEK293T cells were transfected 1224 
with the indicated Cas9 ortholog cloned in the same plasmid backbone, and fused to the same HA epitope tags and 1225 
NLSs. Top panel: anti-HA western blot (EP, empty sgRNA plasmid). Bottom panel: anti-GAPDH western blot, used 1226 
as a loading control. Mobilities of protein markers are indicated. (B) T7E1 analysis of three previously validated 1227 
SpyCas9 guides targeting the AAVS1 locus, in comparison with NmeCas9 guides targeting nearby AAVS1 sites (mean 1228 
± s.e.m., n = 3). (C) Representative T7EI analyses comparing editing efficiencies at the dual target sites DTS1, 1229 
DTS3, DTS7, DTS8, and NTS7, using the indicated Cas9/sgRNA combinations. (D) Quantitation of data from (C) 1230 
(mean ± s.e.m., n = 3). 1231 
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 1232 
Figure 5. Bioinformatic and empirical comparison of NmeCas9 and SpyCas9 off-target sites within the human 1233 
genome. (A) Genome-wide computational (CRISPRseek) predictions of off-target sites for NmeCas9 (with N4GN3 1234 
PAMs) and SpyCas9 (with NGG, NGA, and NAG PAMs) with DTS3, DTS7 and DTS8 sgRNAs. Predicted off-1235 
target sites were binned based on the number of mismatches (up to six) with the guide sequences. (B) GUIDE-Seq 1236 
analysis of off-target sites in HEK293T cells with sgRNAs targeting DTS3, DTS7 and DTS8, using either SpyCas9 1237 
or NmeCas9, and with up to 6 mismatches to the sgRNAs. The numbers of detected off-target sites are indicated at 1238 
the top of each bar. (C) Numbers of independent GUIDE-Seq reads for the on- and off-target sites for all six 1239 
Cas9/sgRNA combinations from (B) (SpyCas9, red; NmeCas9, green), binned by the number of mismatches with 1240 
the corresponding guide. (D) Targeted deep sequencing analysis of lesion efficiencies at on- and off-target sites from 1241 
(A) or (B) with SpyCas9 (left, red) or NmeCas9 (right, green). Data for off-target sites are in grey. For SpyCas9, all 1242 
off-target sites were chosen from (B) based on the highest GUIDE-Seq read counts for each guide (Supplemental 1243 
Table 3). For NmeCas9, in addition to those candidate off-target sites obtained from GUIDE-Seq (C), we also 1244 
assayed one or two potential off-target sites (designated with the “-CS” suffix) predicted by CRISPRseek as the 1245 
closest near-cognate matches with permissive PAMs. Data are mean values ± s.e.m. from three biological replicates 1246 
performed on different days. 1247 
 1248 
Figure 6. Off-target analyses for additional NmeCas9 sgRNAs, targeting sites with consensus and variant PAMs. (A) 1249 
Number of GUIDE-Seq reads for the on-target sites, with the PAM sequences for each site indicated underneath. (B) 1250 
Number of GUIDE-Seq-detected off-target sites using the Bioconductor package GUIDEseq version 1.1.17 [79] 1251 
with default settings except that PAM.size = 8, PAM = "NNNNGATT", min.reads = 2, max.mismatch = 6, 1252 
allowed.mismatch.PAM = 4, PAM.pattern = "NNNNNNNN$", BSgenomeName = Hsapiens, txdb = 1253 
TxDb.Hsapiens.UCSC.hg19.knownGene, orgAnn = org.Hs.egSYMBOL gRNA.size was set to length of the gRNA 1254 
used, and various number of 0’s were added at the beginning of weights to make the length of weights equal to the 1255 
gRNA size.  For example, for gRNA with length 24, weights = c(0,0,0,0,0, 0, 0.014, 0, 0, 0.395, 0.317, 0, 0.389, 1256 
0.079, 0.445, 0.508, 0.613, 0.851, 0.732, 0.828, 0.615, 0.804, 0.685, 0.583) for all sixteen sgRNAs used in (A). (C) 1257 
Lesion efficiencies for the on-target sites as measured by PCR and high-throughput sequencing. Data are mean 1258 
values ± s.e.m. from three biological replicates performed on different days. (D) NmeCas9 lesion efficiencies at the 1259 
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NTS1C (left) and NTS25 (right) on-target sites, and at the off-target sites detected by GUIDE-Seq from (B), as 1260 
measured by PCR and high-throughput sequencing. Data are mean values ± s.e.m. from three biological replicates 1261 
performed on different days. (E) Schematic diagrams of NmeCas9 sgRNA/DNA R-loops for the NTS1C (left) and 1262 
NTS25 (right) sgRNAs, at the GUIDE-Seq-detected on- and off-target sites. Black, DNA residues; boxed nts, PAM; 1263 
red line, NmeCas9 cleavage site; cyan and purple, mismatch/wobble and complementary nts (respectively) in the 1264 
NmeCas9 sgRNA guide region; green, NmeCas9 sgRNA repeat nts. (F) Comparison of NmeCas9 and SpyCas9 1265 
biochemical off-target sites using SITE-Seq analysis. 1266 
 1267 
Figure 7. Guide truncation can suppress off-target editing by NmeCas9. (A) Lesion efficiencies at the NTS1C (on-1268 
target, red) and NTS1C-OT1 (off-target, orange) genomic sites, after editing by NmeCas9 and NTS1C sgRNAs of 1269 
varying lengths, as measured by PCR and high-throughput sequencing. Data are mean values ± s.e.m. from three 1270 
biological replicates performed on different days. (B) As in (A), but using sgRNAs perfectly complementary to the 1271 
NTS1C-OT1 genomic site. 1272 
 1273 
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